Your browser doesn't support javascript.
loading
NLRP3 Inflammasome Mediates Aldosterone-Induced Vascular Damage.
Bruder-Nascimento, Thiago; Ferreira, Nathanne S; Zanotto, Camila Z; Ramalho, Fernanda; Pequeno, Isabela O; Olivon, Vania C; Neves, Karla B; Alves-Lopes, Rheure; Campos, Eduardo; Silva, Carlos Alberto A; Fazan, Rubens; Carlos, Daniela; Mestriner, Fabiola L; Prado, Douglas; Pereira, Felipe V; Braga, Tarcio; Luiz, Joao Paulo M; Cau, Stefany B; Elias, Paula C; Moreira, Ayrton C; Câmara, Niels O; Zamboni, Dario S; Alves-Filho, Jose Carlos; Tostes, Rita C.
Afiliação
  • Bruder-Nascimento T; From Department of Pharmacology (T.B.-N., N.S.F., C.Z.Z., F.R., I.O.P., V.C.O., K.B.N., R.A.-L., E.C., F.L.M., D.P., J.P.M.L., J.C.A.F., R.C.T.), Department of Physiology (C.A.A.S., R.F.), Department of Biochemistry and Immunology (D.C.), Department of Clinical Medicine, Division of Endocrinology (P
  • Ferreira NS; From Department of Pharmacology (T.B.-N., N.S.F., C.Z.Z., F.R., I.O.P., V.C.O., K.B.N., R.A.-L., E.C., F.L.M., D.P., J.P.M.L., J.C.A.F., R.C.T.), Department of Physiology (C.A.A.S., R.F.), Department of Biochemistry and Immunology (D.C.), Department of Clinical Medicine, Division of Endocrinology (P
  • Zanotto CZ; From Department of Pharmacology (T.B.-N., N.S.F., C.Z.Z., F.R., I.O.P., V.C.O., K.B.N., R.A.-L., E.C., F.L.M., D.P., J.P.M.L., J.C.A.F., R.C.T.), Department of Physiology (C.A.A.S., R.F.), Department of Biochemistry and Immunology (D.C.), Department of Clinical Medicine, Division of Endocrinology (P
  • Ramalho F; From Department of Pharmacology (T.B.-N., N.S.F., C.Z.Z., F.R., I.O.P., V.C.O., K.B.N., R.A.-L., E.C., F.L.M., D.P., J.P.M.L., J.C.A.F., R.C.T.), Department of Physiology (C.A.A.S., R.F.), Department of Biochemistry and Immunology (D.C.), Department of Clinical Medicine, Division of Endocrinology (P
  • Pequeno IO; From Department of Pharmacology (T.B.-N., N.S.F., C.Z.Z., F.R., I.O.P., V.C.O., K.B.N., R.A.-L., E.C., F.L.M., D.P., J.P.M.L., J.C.A.F., R.C.T.), Department of Physiology (C.A.A.S., R.F.), Department of Biochemistry and Immunology (D.C.), Department of Clinical Medicine, Division of Endocrinology (P
  • Olivon VC; From Department of Pharmacology (T.B.-N., N.S.F., C.Z.Z., F.R., I.O.P., V.C.O., K.B.N., R.A.-L., E.C., F.L.M., D.P., J.P.M.L., J.C.A.F., R.C.T.), Department of Physiology (C.A.A.S., R.F.), Department of Biochemistry and Immunology (D.C.), Department of Clinical Medicine, Division of Endocrinology (P
  • Neves KB; From Department of Pharmacology (T.B.-N., N.S.F., C.Z.Z., F.R., I.O.P., V.C.O., K.B.N., R.A.-L., E.C., F.L.M., D.P., J.P.M.L., J.C.A.F., R.C.T.), Department of Physiology (C.A.A.S., R.F.), Department of Biochemistry and Immunology (D.C.), Department of Clinical Medicine, Division of Endocrinology (P
  • Alves-Lopes R; From Department of Pharmacology (T.B.-N., N.S.F., C.Z.Z., F.R., I.O.P., V.C.O., K.B.N., R.A.-L., E.C., F.L.M., D.P., J.P.M.L., J.C.A.F., R.C.T.), Department of Physiology (C.A.A.S., R.F.), Department of Biochemistry and Immunology (D.C.), Department of Clinical Medicine, Division of Endocrinology (P
  • Campos E; From Department of Pharmacology (T.B.-N., N.S.F., C.Z.Z., F.R., I.O.P., V.C.O., K.B.N., R.A.-L., E.C., F.L.M., D.P., J.P.M.L., J.C.A.F., R.C.T.), Department of Physiology (C.A.A.S., R.F.), Department of Biochemistry and Immunology (D.C.), Department of Clinical Medicine, Division of Endocrinology (P
  • Silva CA; From Department of Pharmacology (T.B.-N., N.S.F., C.Z.Z., F.R., I.O.P., V.C.O., K.B.N., R.A.-L., E.C., F.L.M., D.P., J.P.M.L., J.C.A.F., R.C.T.), Department of Physiology (C.A.A.S., R.F.), Department of Biochemistry and Immunology (D.C.), Department of Clinical Medicine, Division of Endocrinology (P
  • Fazan R; From Department of Pharmacology (T.B.-N., N.S.F., C.Z.Z., F.R., I.O.P., V.C.O., K.B.N., R.A.-L., E.C., F.L.M., D.P., J.P.M.L., J.C.A.F., R.C.T.), Department of Physiology (C.A.A.S., R.F.), Department of Biochemistry and Immunology (D.C.), Department of Clinical Medicine, Division of Endocrinology (P
  • Carlos D; From Department of Pharmacology (T.B.-N., N.S.F., C.Z.Z., F.R., I.O.P., V.C.O., K.B.N., R.A.-L., E.C., F.L.M., D.P., J.P.M.L., J.C.A.F., R.C.T.), Department of Physiology (C.A.A.S., R.F.), Department of Biochemistry and Immunology (D.C.), Department of Clinical Medicine, Division of Endocrinology (P
  • Mestriner FL; From Department of Pharmacology (T.B.-N., N.S.F., C.Z.Z., F.R., I.O.P., V.C.O., K.B.N., R.A.-L., E.C., F.L.M., D.P., J.P.M.L., J.C.A.F., R.C.T.), Department of Physiology (C.A.A.S., R.F.), Department of Biochemistry and Immunology (D.C.), Department of Clinical Medicine, Division of Endocrinology (P
  • Prado D; From Department of Pharmacology (T.B.-N., N.S.F., C.Z.Z., F.R., I.O.P., V.C.O., K.B.N., R.A.-L., E.C., F.L.M., D.P., J.P.M.L., J.C.A.F., R.C.T.), Department of Physiology (C.A.A.S., R.F.), Department of Biochemistry and Immunology (D.C.), Department of Clinical Medicine, Division of Endocrinology (P
  • Pereira FV; From Department of Pharmacology (T.B.-N., N.S.F., C.Z.Z., F.R., I.O.P., V.C.O., K.B.N., R.A.-L., E.C., F.L.M., D.P., J.P.M.L., J.C.A.F., R.C.T.), Department of Physiology (C.A.A.S., R.F.), Department of Biochemistry and Immunology (D.C.), Department of Clinical Medicine, Division of Endocrinology (P
  • Braga T; From Department of Pharmacology (T.B.-N., N.S.F., C.Z.Z., F.R., I.O.P., V.C.O., K.B.N., R.A.-L., E.C., F.L.M., D.P., J.P.M.L., J.C.A.F., R.C.T.), Department of Physiology (C.A.A.S., R.F.), Department of Biochemistry and Immunology (D.C.), Department of Clinical Medicine, Division of Endocrinology (P
  • Luiz JP; From Department of Pharmacology (T.B.-N., N.S.F., C.Z.Z., F.R., I.O.P., V.C.O., K.B.N., R.A.-L., E.C., F.L.M., D.P., J.P.M.L., J.C.A.F., R.C.T.), Department of Physiology (C.A.A.S., R.F.), Department of Biochemistry and Immunology (D.C.), Department of Clinical Medicine, Division of Endocrinology (P
  • Cau SB; From Department of Pharmacology (T.B.-N., N.S.F., C.Z.Z., F.R., I.O.P., V.C.O., K.B.N., R.A.-L., E.C., F.L.M., D.P., J.P.M.L., J.C.A.F., R.C.T.), Department of Physiology (C.A.A.S., R.F.), Department of Biochemistry and Immunology (D.C.), Department of Clinical Medicine, Division of Endocrinology (P
  • Elias PC; From Department of Pharmacology (T.B.-N., N.S.F., C.Z.Z., F.R., I.O.P., V.C.O., K.B.N., R.A.-L., E.C., F.L.M., D.P., J.P.M.L., J.C.A.F., R.C.T.), Department of Physiology (C.A.A.S., R.F.), Department of Biochemistry and Immunology (D.C.), Department of Clinical Medicine, Division of Endocrinology (P
  • Moreira AC; From Department of Pharmacology (T.B.-N., N.S.F., C.Z.Z., F.R., I.O.P., V.C.O., K.B.N., R.A.-L., E.C., F.L.M., D.P., J.P.M.L., J.C.A.F., R.C.T.), Department of Physiology (C.A.A.S., R.F.), Department of Biochemistry and Immunology (D.C.), Department of Clinical Medicine, Division of Endocrinology (P
  • Câmara NO; From Department of Pharmacology (T.B.-N., N.S.F., C.Z.Z., F.R., I.O.P., V.C.O., K.B.N., R.A.-L., E.C., F.L.M., D.P., J.P.M.L., J.C.A.F., R.C.T.), Department of Physiology (C.A.A.S., R.F.), Department of Biochemistry and Immunology (D.C.), Department of Clinical Medicine, Division of Endocrinology (P
  • Zamboni DS; From Department of Pharmacology (T.B.-N., N.S.F., C.Z.Z., F.R., I.O.P., V.C.O., K.B.N., R.A.-L., E.C., F.L.M., D.P., J.P.M.L., J.C.A.F., R.C.T.), Department of Physiology (C.A.A.S., R.F.), Department of Biochemistry and Immunology (D.C.), Department of Clinical Medicine, Division of Endocrinology (P
  • Alves-Filho JC; From Department of Pharmacology (T.B.-N., N.S.F., C.Z.Z., F.R., I.O.P., V.C.O., K.B.N., R.A.-L., E.C., F.L.M., D.P., J.P.M.L., J.C.A.F., R.C.T.), Department of Physiology (C.A.A.S., R.F.), Department of Biochemistry and Immunology (D.C.), Department of Clinical Medicine, Division of Endocrinology (P
  • Tostes RC; From Department of Pharmacology (T.B.-N., N.S.F., C.Z.Z., F.R., I.O.P., V.C.O., K.B.N., R.A.-L., E.C., F.L.M., D.P., J.P.M.L., J.C.A.F., R.C.T.), Department of Physiology (C.A.A.S., R.F.), Department of Biochemistry and Immunology (D.C.), Department of Clinical Medicine, Division of Endocrinology (P
Circulation ; 134(23): 1866-1880, 2016 Dec 06.
Article em En | MEDLINE | ID: mdl-27803035
ABSTRACT

BACKGROUND:

Inflammation is a key feature of aldosterone-induced vascular damage and dysfunction, but molecular mechanisms by which aldosterone triggers inflammation remain unclear. The NLRP3 inflammasome is a pivotal immune sensor that recognizes endogenous danger signals triggering sterile inflammation.

METHODS:

We analyzed vascular function and inflammatory profile of wild-type (WT), NLRP3 knockout (NLRP3-/-), caspase-1 knockout (Casp-1-/-), and interleukin-1 receptor knockout (IL-1R-/-) mice treated with vehicle or aldosterone (600 µg·kg-1·d-1 for 14 days through osmotic mini-pump) while receiving 1% saline to drink.

RESULTS:

Here, we show that NLRP3 inflammasome plays a central role in aldosterone-induced vascular dysfunction. Long-term infusion of aldosterone in mice resulted in elevation of plasma interleukin-1ß levels and vascular abnormalities. Mice lacking the IL-1R or the inflammasome components NLRP3 and caspase-1 were protected from aldosterone-induced vascular damage. In vitro, aldosterone stimulated NLRP3-dependent interleukin-1ß secretion by bone marrow-derived macrophages by activating nuclear factor-κB signaling and reactive oxygen species generation. Moreover, chimeric mice reconstituted with NLRP3-deficient hematopoietic cells showed that NLRP3 in immune cells mediates aldosterone-induced vascular damage. In addition, aldosterone increased the expression of NLRP3, active caspase-1, and mature interleukin-1ß in human peripheral blood mononuclear cells. Hypertensive patients with hyperaldosteronism or normal levels of aldosterone exhibited increased activity of NLRP3 inflammasome, suggesting that the effect of hyperaldosteronism on the inflammasome may be mediated through high blood pressure.

CONCLUSIONS:

Together, these data demonstrate that NLRP3 inflammasome, through activation of IL-1R, is critically involved in the deleterious vascular effects of aldosterone, placing NLRP3 as a potential target for therapeutic interventions in conditions with high aldosterone levels.
Assuntos
Palavras-chave
Buscar no Google
Base de dados: MEDLINE Assunto principal: Aldosterona / Proteína 3 que Contém Domínio de Pirina da Família NLR / Artérias Mesentéricas Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Buscar no Google
Base de dados: MEDLINE Assunto principal: Aldosterona / Proteína 3 que Contém Domínio de Pirina da Família NLR / Artérias Mesentéricas Idioma: En Ano de publicação: 2016 Tipo de documento: Article